Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities

Aliment Pharmacol Ther. 2023 May;57(10):1186-1187. doi: 10.1111/apt.17484.

Jannis Kountouras¹, Apostolis Papaefthymiou^{1

2

3}, Stergios A Polyzos³, Evangelos Kazakos^{1

4}, Dimitrios Tzilves⁵, Maria Touloumtzi¹, Dimitrios Chatzopoulos¹, Maria Tzitiridou-Chatzopoulou^{1

4}, Christos Liatsos⁶, Christos Zavos¹, John Kavaliotis¹, Hasan Kulaksiz⁷, Michael Doulberis^{1

3

7

8}

¹ Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece.
² Pancreaticobiliary Medicine Unit, University College London Hospitals (UCLH), London, UK.
³ First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece.
⁴ Midwifery Department, School of Healthcare Sciences, University of West Macedonia, Kozani, Macedonia, Greece.
⁵ Gastroenterology Department, Theageneio Hospital, Thessaloniki, Macedonia, Greece.
⁶ Department of Gastroenterology, General Military Hospital of Athens, Attiki, Greece.
⁷ Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland.
⁸ Department of Gastroenterology and Hepatology, University of Zurich, Zurich, Switzerland.

No abstract available

Publication types